Next Article in Journal
Current Search through Liquid Biopsy of Effective Biomarkers for Early Cancer Diagnosis into the Rich Cargoes of Extracellular Vesicles
Previous Article in Journal
Advances and Perspectives in Tissue Culture and Genetic Engineering of Cannabis
Review

Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?

1
Tomas Lindahl Nobel Laureate Laboratory, Precision Medicine Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China
2
Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
3
Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, 3015 CN Rotterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Vasso Apostolopoulos
Int. J. Mol. Sci. 2021, 22(11), 5672; https://doi.org/10.3390/ijms22115672
Received: 8 May 2021 / Revised: 20 May 2021 / Accepted: 25 May 2021 / Published: 26 May 2021
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
COVID-19 has rapidly become a pandemic worldwide, causing extensive and long-term health issues. There is an urgent need to identify therapies that limit SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Unbalanced lung inflammation is a common feature in severe COVID-19 patients; therefore, reducing lung inflammation can undoubtedly benefit the clinical manifestations. Histamine H1 receptor (H1 receptor) antagonists are widely prescribed medications to treat allergic diseases, while recently it has emerged that they show significant promise as anti-SARS-CoV-2 agents. Here, we briefly summarize the novel use of H1 receptor antagonists in combating SARS-CoV-2 infection. We also describe the potential antiviral mechanisms of H1 receptor antagonists on SARS-CoV-2. Finally, the opportunities and challenges of the use of H1 receptor antagonists in managing COVID-19 are discussed. View Full-Text
Keywords: COVID-19; NF-κB signaling; H1 receptor antagonists; treatment; drugs COVID-19; NF-κB signaling; H1 receptor antagonists; treatment; drugs
Show Figures

Figure 1

MDPI and ACS Style

Qu, C.; Fuhler, G.M.; Pan, Y. Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19? Int. J. Mol. Sci. 2021, 22, 5672. https://doi.org/10.3390/ijms22115672

AMA Style

Qu C, Fuhler GM, Pan Y. Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19? International Journal of Molecular Sciences. 2021; 22(11):5672. https://doi.org/10.3390/ijms22115672

Chicago/Turabian Style

Qu, Changbo, Gwenny M. Fuhler, and Yihang Pan. 2021. "Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?" International Journal of Molecular Sciences 22, no. 11: 5672. https://doi.org/10.3390/ijms22115672

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop